

David K Simon

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9475963/david-k-simon-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

5,373
citations

34
h-index

73
g-index

76
ext. papers

6,252
ext. citations

6.9
avg, IF

5.32
L-index

#	Paper	IF	Citations
74	Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. <i>Cell</i> , 2006 , 127, 397-408	56.2	1689
73	High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. <i>Human Molecular Genetics</i> , 2002 , 11, 133-45	5.6	262
72	A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. <i>JAMA Neurology</i> , 2014 , 71, 543-52	17.2	239
71	Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. <i>Annals of Neurology</i> , 2012 , 71, 370-84	9.4	214
70	Dystonia. <i>New England Journal of Medicine</i> , 2006 , 355, 818-29	59.2	205
69	Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. <i>Journal of Biological Chemistry</i> , 2005 , 280, 40398-401	5.4	155
68	Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 584-93	27.4	153
67	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019 , 92, 329-337	6.5	144
66	Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. <i>Clinics in Geriatric Medicine</i> , 2020 , 36, 1-12	3.8	143
65	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017 , 32, 319-324	7	111
64	Noninvasive brain stimulation for Parkinson's disease and dystonia. <i>Neurotherapeutics</i> , 2008 , 5, 345-61	6.4	103
63	Association of cumulative lead exposure with Parkinson's disease. <i>Environmental Health Perspectives</i> , 2010 , 118, 1609-13	8.4	97
62	Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. <i>Neurobiology of Aging</i> , 2004 , 25, 71-81	5.6	95
61	Responses of retinal axons in vivo and in vitro to position-encoding molecules in the embryonic superior colliculus. <i>Neuron</i> , 1992 , 9, 977-89	13.9	90
60	Limited topographic specificity in the targeting and branching of mammalian retinal axons. <i>Developmental Biology</i> , 1990 , 137, 125-34	3.1	87
59	Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. <i>PLoS ONE</i> , 2010 , 5, e12333	3.7	80
58	Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. <i>Annals of Neurology</i> , 2012 , 71, 850-4	9.4	79

57	A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. <i>Archives of Neurology</i> , 2003 , 60, 722-5		79
56	Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. <i>Antioxidants and Redox Signaling</i> , 2009 , 11, 509-28	8.4	77
55	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , 2019 , 34, 1839-1850	7	69
54	Somatic mitochondrial DNA mutations in single neurons and glia. <i>Neurobiology of Aging</i> , 2005 , 26, 1343-55	5.6	69
53	Frequency of the D620N mutation in VPS35 in Parkinson disease. <i>Archives of Neurology</i> , 2012 , 69, 1360-4		66
52	Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. <i>Human Molecular Genetics</i> , 2014 , 23, 637-47	5.6	63
51	Relationship of retinotopic ordering of axons in the optic pathway to the formation of visual maps in central targets. <i>Journal of Comparative Neurology</i> , 1991 , 307, 393-404	3.4	62
50	An inverse-Warburg effect and the origin of Alzheimer's disease. <i>Biogerontology</i> , 2012 , 13, 583-94	4.5	59
49	Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts. <i>Neurology: Genetics</i> , 2019 , 5, e348	3.8	57
48	Pgc-1 β overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. <i>PLoS ONE</i> , 2012 , 7, e48925	3.7	52
47	Plasticity in the development of topographic order in the mammalian retinocollicular projection. <i>Developmental Biology</i> , 1994 , 162, 384-93	3.1	47
46	Attenuation of free radical production and paracrystalline inclusions by creatine supplementation in a patient with a novel cytochrome b mutation. <i>Muscle and Nerve</i> , 2004 , 29, 537-47	3.4	41
45	Influence of position along the medial-lateral axis of the superior colliculus on the topographic targeting and survival of retinal axons. <i>Developmental Brain Research</i> , 1992 , 69, 167-72		40
44	The inverse association of cancer and Alzheimer's: a bioenergetic mechanism. <i>Journal of the Royal Society Interface</i> , 2013 , 10, 20130006	4.1	38
43	Do mtDNA deletions drive premature aging in mtDNA mutator mice?. <i>Aging Cell</i> , 2009 , 8, 502-6	9.9	37
42	Singing in groups for Parkinson's disease (SING-PD): a pilot study of group singing therapy for PD-related voice/speech disorders. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 548-52	3.6	36
41	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2021 , 78, 312-320	17.2	34
40	Head injury at early ages is associated with risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 23, 57-61	3.6	33

39	A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. <i>Neurogenetics</i> , 2003 , 4, 199-205	3	32
38	Caffeine and progression of Parkinson disease. <i>Clinical Neuropharmacology</i> , 2008 , 31, 189-96	1.4	30
37	Mitochondrial complex I gene variant associated with early age at onset in spinocerebellar ataxia type 2. <i>Archives of Neurology</i> , 2007 , 64, 1042-4		29
36	Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. <i>BMC Medical Genetics</i> , 2010 , 11, 53	2.1	26
35	Metabolomic analysis of exercise effects in the POLG mitochondrial DNA mutator mouse brain. <i>Neurobiology of Aging</i> , 2015 , 36, 2972-2983	5.6	23
34	Behavioral and metabolic characterization of heterozygous and homozygous POLG mutator mice. <i>Mitochondrion</i> , 2013 , 13, 282-91	4.9	23
33	Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. <i>Journal of Parkinsons Disease</i> , 2015 , 5, 731-6	5.3	20
32	Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. <i>Journal of the Neurological Sciences</i> , 2017 , 377, 137-143	3.2	19
31	MELAS syndrome, cardiomyopathy, rhabdomyolysis, and autism associated with the A3260G mitochondrial DNA mutation. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 402, 443-7	3.4	19
30	Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. <i>Clinical Neuropharmacology</i> , 2015 , 38, 163-9	1.4	18
29	Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , 2017 , 375, 355-359	3.2	17
28	Differences in the Presentation and Progression of Parkinson's Disease by Sex. <i>Movement Disorders</i> , 2021 , 36, 106-117	7	16
27	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 926-939	27.4	16
26	Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. <i>Neurology</i> , 2017 , 89, 1789-1794	6.5	15
25	The c.-237_236GA>TT THAP1 sequence variant does not increase risk for primary dystonia. <i>Movement Disorders</i> , 2011 , 26, 549-52	7	15
24	Mistaken diagnosis of psychogenic gait disorder in a man with status cataplecticus ("limp man syndrome"). <i>Movement Disorders</i> , 2004 , 19, 838-840	7	15
23	Inverse probability weighted Cox regression for doubly truncated data. <i>Biometrics</i> , 2018 , 74, 481-487	1.8	13
22	Autonomic and electrocardiographic findings in Parkinson's disease. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017 , 205, 93-98	2.4	11

21	Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice. <i>Neurotoxicology and Teratology</i> , 2014 , 46, 62-7	3.9	11
20	Do somatic mitochondrial DNA mutations contribute to Parkinson's disease?. <i>Parkinsons Disease</i> , 2011 , 2011, 659694	2.6	10
19	No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. <i>PLoS ONE</i> , 2014 , 9, e112287	3.7	9
18	VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology. <i>Neurobiology of Disease</i> , 2020 , 145, 105056	7.5	9
17	Complicated spontaneous intracranial hypotension treated with intrathecal saline infusion. <i>Practical Neurology</i> , 2016 , 16, 146-9	2.4	8
16	Clinical Impact of 123I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center. <i>Neurodegenerative Diseases</i> , 2017 , 17, 38-43	2.3	8
15	Computationally simple estimation and improved efficiency for special cases of double truncation. <i>Lifetime Data Analysis</i> , 2014 , 20, 335-54	1.3	8
14	Mitochondrial DNA mutations in Parkinson's disease brain. <i>Acta Neuropathologica Communications</i> , 2017 , 5, 33	7.3	7
13	A frameshift mitochondrial complex I gene mutation in a patient with dystonia and cataracts: is the mutation pathogenic?. <i>Journal of Medical Genetics</i> , 2001 , 38, 58-61	5.8	7
12	Altered muscle electrical tissue properties in a mouse model of premature aging. <i>Muscle and Nerve</i> , 2019 , 60, 801-810	3.4	6
11	Genetic risk factors in Parkinson's disease: single gene effects and interactions of genotypes. <i>Journal of Neurology</i> , 2012 , 259, 2503-5	5.5	6
10	Nilotinib in Patients with Advanced Parkinson's Disease: A Randomized Phase 2A Study (NILO-PD)		6
9	Transportation innovation to aid Parkinson disease trial recruitment. <i>Contemporary Clinical Trials Communications</i> , 2019 , 16, 100449	1.8	4
8	Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. <i>Parkinsonism and Related Disorders</i> , 2020 , 70, 96-102	3.6	3
7	Boxing Exercises as Therapy for Parkinson Disease. <i>Topics in Geriatric Rehabilitation</i> , 2020 , 36, 160-165	0.7	3
6	Efficacy of Deep Brain Stimulation in a Patient with Genetically Confirmed Chorea-Acanthocytosis. <i>Case Reports in Neurology</i> , 2019 , 11, 199-204	1	2
5	Mitochondria and Parkinson's disease. <i>Parkinsons Disease</i> , 2011 , 2011, 261791	2.6	2
4	The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 781-782	7	1

3	The utility of laser-generated visual-cueing in Parkinsonian patients with gait freezing. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 401	3.6
2	A New Approach to the Development of Disease-Modifying Therapies for PD. <i>Movement Disorders</i> , 2021 , 36, 1281	7
1	Associations between exercise classes and self-reported exercise by people with Parkinson's disease at Parkinson's foundation centers of excellence.. <i>Clinical Parkinsonism & Related Disorders</i> , 2022 , 6, 100137	0.9